Acquiring Company
Mentari Therapeutics
Acquired Company
InMed Pharmaceuticals
San Francisco
VancouverBiotechnologyHealth CareTherapeuticsHealthcareDescription
Mentari Therapeutics completed its previously disclosed merger with InMed Pharmaceuticals Inc. on November 9, 2026, and began trading on Nasdaq as MTRI. The combined company closed approximately $490 million in private placement financings immediately before the merger. Mentari also appointed Todd Shegog to its Board of Directors, where he will chair the Audit Committee.
Who to call at Mentari Therapeutics, and when
When Mentari Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Mentari Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mentari Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mentari Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mentari Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired InMed Pharmaceuticals?
InMed Pharmaceuticals was acquired by Mentari Therapeutics, based in San Francisco. The deal was reported on November 9, 2026. Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition. Mentari Therapeutics is privately held and operates in Biotechnology.
When did Mentari Therapeutics acquire InMed Pharmaceuticals?
Mentari Therapeutics's acquisition of InMed Pharmaceuticals was reported on November 9, 2026. Mentari Therapeutics completed its previously disclosed merger with InMed Pharmaceuticals Inc. on November 9, 2026, and began trading on Nasdaq as MTRI. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does InMed Pharmaceuticals do?
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. It is publicly traded (INM), operating in Healthcare, and is based in Vancouver.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.